転移性乳がんにおける DB-1303 と研究者が選択した化学療法の研究
疾患が進行したヒト上皮成長因子受容体 2 (HER2) 低下、ホルモン受容体陽性 (HR+) の転移性乳がん患者を対象とした、DB-1303 と医師が選択した化学療法の第 3 相無作為化多施設非盲検試験内分泌療法 (ET) (DYNASTY-Breast02)
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry [IHC]2+/in situ hybridization [ISH]- and IHC 1+) population.
調査の概要
詳細な説明
The study is a Phase III, Randomized, Multi-center, Open-label study in HER2-low, HR+ metastatic breast cancer subjects whose disease has progressed on at least 2 lines of prior ET or within 6 months of first line ET + Cyclin-dependent kinase (CDK) 4/6 inhibitor in the metastatic setting. The primary purpose of the study is to determine the efficacy and safety of DB-1303/BNT323 compared with investigator's choice single agent chemotherapy in the target population. Approximately 532 subjects with HER2 IHC 2+/ISH- and IHC 1+ (HER2-low] expression will be randomized 1:1 across approximately 255 centers globally to receive either DB-1303 or investigator's choice single agent chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) until Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85704
- Research Site 1141-0
-
-
California
-
Fullerton、California、アメリカ、92835
- Research Site 1114-0
-
Los Angeles、California、アメリカ、90095
- Research Site 1107-0
-
Orange、California、アメリカ、92868-3201
- Research Site 1118-0
-
Sacramento、California、アメリカ、95814
- Research Site 1143-0
-
Santa Barbara、California、アメリカ、93105
- Research Site 1132-0
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- Research Site 1137-0
-
Lone Tree、Colorado、アメリカ、80124
- Research Site 1129-0
-
-
Florida
-
Jacksonville、Florida、アメリカ、32256
- Research Site 1154-0
-
Miami、Florida、アメリカ、33136
- Research Site 1145-0
-
Orange City、Florida、アメリカ、32763
- Research Site 1150-0
-
Palm Bay、Florida、アメリカ、32909
- Research Site 1125-0
-
-
Georgia
-
Athens、Georgia、アメリカ、30607
- Research Site 1155-0
-
Savannah、Georgia、アメリカ、31405
- Research Site 1110-0
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Research Site 1147-0
-
Chicago Ridge、Illinois、アメリカ、60415
- Research Site 1124-0
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46804
- Research Site 1152-0
-
-
Kansas
-
Merriam、Kansas、アメリカ、66204
- Research Site 1106-0
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40202
- Research Site 1104-0
-
-
Maryland
-
Silver Spring、Maryland、アメリカ、20904
- Research Site 1122-0
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- Research Site 1109-0
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Research Site 1158-0
-
Florham Park、New Jersey、アメリカ、07932
- Research Site 1111-0
-
-
New Mexico
-
Sante Fe、New Mexico、アメリカ、87505
- Research Site 1157-0
-
-
New York
-
Staten Island、New York、アメリカ、10314
- Research Site 1148-0
-
Westbury、New York、アメリカ、11590
- Research Site 1105-0
-
-
North Carolina
-
Chapel Hil、North Carolina、アメリカ、27599
- Research Site 1144-0
-
-
Ohio
-
Akron、Ohio、アメリカ、44305
- Research Site 1138-0
-
Cincinnati、Ohio、アメリカ、45220
- Research Site 1160-0
-
-
Oregon
-
Eugene、Oregon、アメリカ、97401-8122
- Research Site 1133-0
-
Tigard、Oregon、アメリカ、97223
- Research Site 1126-0
-
-
Pennsylvania
-
Broomall、Pennsylvania、アメリカ、19008
- Research Site 1134-0
-
Horsham、Pennsylvania、アメリカ、19044
- Research Site 1123-0
-
-
Tennessee
-
Knoxville、Tennessee、アメリカ、37909
- Research Site 1149-0
-
Nashville、Tennessee、アメリカ、37203
- Research Site 1102-0
-
Nashville、Tennessee、アメリカ、37203
- Research Site 1159-0
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- Research Site 1101-0
-
Denison、Texas、アメリカ、75020
- Research Site 1116-0
-
Houston、Texas、アメリカ、77030
- Research Site 1115-0
-
San Antonio、Texas、アメリカ、78240
- Research Site 1117-0
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84124
- Research Site 1130-0
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- Research Site 1108-0
-
Fairfax、Virginia、アメリカ、22031
- Research Site 1131-0
-
Roanake、Virginia、アメリカ、24014
- Research Site 1127-0
-
-
-
-
Buenos Aires
-
Bahía Blanca、Buenos Aires、アルゼンチン、B8001HXM
- Research Site 5411-0
-
CABA、Buenos Aires、アルゼンチン、C1015ABO
- Research Site 5414-0
-
La Plata、Buenos Aires、アルゼンチン、B1902CMJ
- Research Site 5405-0
-
Mar del Plata、Buenos Aires、アルゼンチン、7600
- Research Site 5413-0
-
Quilmes、Buenos Aires、アルゼンチン、B1878GEG
- Research Site 5408-0
-
-
Ciudad Autonoma Buenos Aires
-
CABA、Ciudad Autonoma Buenos Aires、アルゼンチン、C1426ANZ
- Research Site 5403-0
-
Ciudad Autonoma Buenos Aires、Ciudad Autonoma Buenos Aires、アルゼンチン、1431
- Research Site 5407-0
-
Ciudad Autonoma Buenos Aires、Ciudad Autonoma Buenos Aires、アルゼンチン、C1280AEB
- Research Site 5409-0
-
-
Córdoba Province
-
Córdoba、Córdoba Province、アルゼンチン、X5008HHW
- Research Site 5412-0
-
-
Río Negro Province
-
Viedma、Río Negro Province、アルゼンチン、R8500ACE
- Research Site 5402-0
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、アルゼンチン、2000
- Research Site 5401-0
-
Rosario、Santa Fe Province、アルゼンチン、S2000KZE
- Research Site 5406-0
-
-
Tucumán Province
-
San Miguel de Tucumán、Tucumán Province、アルゼンチン、T4000AXL
- Research Site 5404-0
-
-
-
-
Cornwall
-
Truro、Cornwall、イギリス、TR1 3LJ
- Research Site 4404-0
-
-
Greater London
-
London、Greater London、イギリス、EC1A 7BE
- Research Site 4408-0
-
London、Greater London、イギリス、NW1 2PG
- Research Site 4411-0
-
London、Greater London、イギリス、SE1 9RT
- Research Site 4406-0
-
London、Greater London、イギリス、SW36JJ
- Research Site 4416-0
-
London、Greater London、イギリス、W1G 6AD
- Research Site 4409-0
-
Southampton、Greater London、イギリス、NW1 2PG
- Research Site 4413-0
-
-
Greater Manchester
-
Manchester、Greater Manchester、イギリス、M20 4BX
- Research Site 4402-0
-
-
Kent
-
Maidstone、Kent、イギリス、ME16 9QQ
- Research Site 4415-0
-
-
Middlesex
-
Middlesex、Middlesex、イギリス、HA6 2RN
- Research Site 4403-0
-
-
Nottingham
-
Nottingham、Nottingham、イギリス、NG5 1PB
- Research Site 4401-0
-
-
Somerset
-
Bath、Somerset、イギリス、BA1 3NG
- Research Site 4414-0
-
-
South Glamorgan
-
Cardiff、South Glamorgan、イギリス、CF14 2TL
- Research Site 4410-0
-
-
Strathclyde
-
Glasgow、Strathclyde、イギリス、G12 0YN
- Research Site 4405-0
-
-
West Yorkshire
-
Leeds、West Yorkshire、イギリス、LS9 7TF
- Research Site 4407-0
-
-
-
-
-
Ashdod、イスラエル、7747629
- Research Site 9710-0
-
Haifa、イスラエル、3109601
- Research Site 9706-0
-
Haifa、イスラエル、3436212
- Research Site 9708-0
-
Jerusalem、イスラエル、9103102
- Research Site 9702-0
-
Jerusalem、イスラエル、91120
- Research Site 9707-0
-
Kfar Saba、イスラエル、4428164
- Research Site 9703-0
-
Petah Tikva、イスラエル、4941492
- Research Site 9704-0
-
Ramat Gan、イスラエル、52621
- Research Site 9709-0
-
Rehovot、イスラエル、7610001
- Research Site 9705-0
-
Tel Aviv、イスラエル、64239
- Research Site 9701-0
-
-
-
-
-
Naples、イタリア、80131
- Research Site 3909-0
-
-
Bergamo
-
Bergamo、Bergamo、イタリア、24125
- Research Site 3908-0
-
-
Brescia
-
Brescia、Brescia、イタリア、25124
- Research Site 3907-0
-
-
Catania
-
Catania、Catania、イタリア、95123
- Research Site 3901-0
-
-
Catanzaro
-
Catanzaro、Catanzaro、イタリア、88100
- Research Site 3903-0
-
-
Milano
-
Milan、Milano、イタリア、20132
- Research Site 3906-0
-
Milan、Milano、イタリア、20133
- Research Site 3911-0
-
Milan、Milano、イタリア、20141
- Research Site 3904-0
-
-
Pavia
-
Pavia、Pavia、イタリア、27100
- Research Site 3902-0
-
-
Verona
-
Verona、Verona、イタリア、37124
- Research Site 3905-0
-
-
-
-
New South Wales
-
Camperdown、New South Wales、オーストラリア、2050
- Research Site 6108-0
-
Kingswood、New South Wales、オーストラリア、2747
- Research Site 6116-0
-
Liverpool、New South Wales、オーストラリア、2170
- Research Site 6109-0
-
Sydney、New South Wales、オーストラリア、2109
- Research Site 6102-0
-
-
Queensland
-
Birtinya、Queensland、オーストラリア、4575
- Research Site 6106-0
-
South Brisbane、Queensland、オーストラリア、4101
- Research Site 6101-0
-
Southport、Queensland、オーストラリア、4215
- Research Site 6107-0
-
Townsville、Queensland、オーストラリア、4814
- Research Site 6104-0
-
-
South Australia
-
Adelaide、South Australia、オーストラリア、2155
- Research Site 6110-0
-
-
Victoria
-
Bendigo、Victoria、オーストラリア、3550
- Research Site 6103-0
-
St Albans、Victoria、オーストラリア、3021
- Research Site 6105-0
-
Traralgon、Victoria、オーストラリア、3844
- Research Site 6113-0
-
-
Western Australia
-
Perth、Western Australia、オーストラリア、6009
- Research Site 6114-0
-
-
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- Research Site 1007-0
-
-
Ontario
-
Brampton、Ontario、カナダ、L6R 3J7
- Research Site 1003-0
-
Toronto、Ontario、カナダ、M2K 1E1
- Research Site 1001-0
-
-
Quebec
-
Montreal、Quebec、カナダ、H3T 1E2
- Research Site 1004-0
-
Montreal、Quebec、カナダ、H3T 1M5
- Research Site 1005-0
-
Montreal、Quebec、カナダ、H4A 3J1
- Research Site 1006-0
-
Sherbrooke、Quebec、カナダ、J1H5N4
- Research Site 1002-0
-
-
-
-
Barcelona
-
Barcelona、Barcelona、スペイン、08003
- Research Site 3410-0
-
Barcelona、Barcelona、スペイン、08023
- Research Site 3402-0
-
Barcelona、Barcelona、スペイン、08036
- Research Site 3404-0
-
Sant Cugat del Vallès、Barcelona、スペイン、08190
- Research Site 3403-0
-
-
La Coruña
-
Santiago de Compostela、La Coruña、スペイン、15706
- Research Site 3409-0
-
-
Madrid
-
Madrid、Madrid、スペイン、28003
- Research Site 3416-0
-
Madrid、Madrid、スペイン、28040
- Research Site 3407-0
-
Madrid、Madrid、スペイン、28040
- Research Site 3414-0
-
Madrid、Madrid、スペイン、28050
- Research Site 3401-0
-
Majadahonda、Madrid、スペイン、28220
- Research Site 3406-0
-
Pozuelo de Alarcón、Madrid、スペイン、28223
- Research Site 3411-0
-
-
Malaga
-
Málaga、Malaga、スペイン、29016
- Research Site 3418-0
-
-
Málaga
-
Málaga、Málaga、スペイン、29010
- Research Site 3415-0
-
-
Navarre
-
Pamplona、Navarre、スペイン、31008
- Research Site 3405-0
-
-
Sevilla
-
Seville、Sevilla、スペイン、41009
- Research Site 3408-0
-
Seville、Sevilla、スペイン、41013
- Research Site 3413-0
-
Seville、Sevilla、スペイン、41013
- Research Site 3417-0
-
-
Valencia
-
Valencia、Valencia、スペイン、46010
- Research Site 3412-0
-
-
-
-
-
Adana、トルコ(Türkiye)、01230
- Research Site 9001-0
-
Ankara、トルコ(Türkiye)、06010
- Research Site 9002-0
-
Ankara、トルコ(Türkiye)、06100
- Research Site 9006-0
-
Ankara、トルコ(Türkiye)、06105
- Research Site 9003-0
-
Ankara、トルコ(Türkiye)、06800
- Research Site 9004-0
-
Diyarbakır、トルコ(Türkiye)、21280
- Research Site 9009-0
-
Istanbul、トルコ(Türkiye)、34147
- Research Site 9008-0
-
Istanbul、トルコ(Türkiye)、34890
- Research Site 9012-0
-
Izmir、トルコ(Türkiye)、35575
- Research Site 9010-0
-
Mersin、トルコ(Türkiye)、33240
- Research Site 9011-0
-
Samsun、トルコ(Türkiye)、55139
- Research Site 9007-0
-
-
-
-
Bavaria
-
Erlangen、Bavaria、ドイツ、91054
- Research Site 4907-0
-
-
Hesse
-
Wiesbaden、Hesse、ドイツ、65199
- Research Site 4909-0
-
-
North Rhine-Westphalia
-
Bottrop、North Rhine-Westphalia、ドイツ、46236
- Research Site 4904-0
-
Cologne、North Rhine-Westphalia、ドイツ、50931
- Research Site 4902-0
-
Witten、North Rhine-Westphalia、ドイツ、58452
- Research Site 4901-0
-
-
Saxony
-
Dresden、Saxony、ドイツ、01307
- Research Site 4903-0
-
-
State of Berlin
-
Berlin、State of Berlin、ドイツ、10967
- Research Site 4905-0
-
Berlin、State of Berlin、ドイツ、13125
- Research Site 4906-0
-
-
-
-
-
Budapest、ハンガリー、1082
- Research Site 3603-0
-
Kecskemét、ハンガリー、Kecskemet
- Research Site 3604-0
-
Salgótarján、ハンガリー、3100
- Research Site 3602-0
-
Tatabánya、ハンガリー、2800
- Research Site 3607-0
-
Zalaegerszeg、ハンガリー、8900
- Research Site 3605-0
-
-
Gyor
-
Győr、Gyor、ハンガリー、9024
- Research Site 3606-0
-
-
-
-
Bouches-du-Rhône
-
Marseille、Bouches-du-Rhône、フランス、13915
- Research Site 3311-0
-
-
Charente Maritime
-
La Rochelle、Charente Maritime、フランス、17019
- Research Site 3303-0
-
-
Doubs
-
Besançon、Doubs、フランス、25000
- Research Site 3312-0
-
-
Gard
-
Nîmes、Gard、フランス、30029
- Research Site 3308-0
-
-
Gironde
-
Bordeaux、Gironde、フランス、33077
- Research Site 3314-0
-
-
Haute Garonne
-
Toulouse、Haute Garonne、フランス、31059
- Research Site 3305-0
-
-
Haute Vienne
-
Limoges、Haute Vienne、フランス、87000
- Research Site 3309-0
-
-
Herault
-
Montpellier、Herault、フランス、34070
- Research Site 3304-0
-
-
Loire Atlantique
-
Saint-Herblain、Loire Atlantique、フランス、44800
- Research Site 3310-0
-
-
Maine et Loire
-
Angers、Maine et Loire、フランス、49055
- Research Site 3301-0
-
-
Nord
-
Lille、Nord、フランス、59020
- Research Site 3315-0
-
-
Paris
-
Paris、Paris、フランス、75010
- Research Site 3316-0
-
-
Pyrenees Atlantiques
-
Bayonne、Pyrenees Atlantiques、フランス、64109
- Research Site 3306-0
-
-
Rhone
-
Pierre-Bénite、Rhone、フランス、69495
- Research Site 3318-0
-
-
Seine Maritime
-
Rouen、Seine Maritime、フランス、76038
- Research Site 3313-0
-
-
Vaculuse
-
Avignon、Vaculuse、フランス、84918
- Research Site 3307-0
-
-
Val de Marne
-
Créteil、Val de Marne、フランス、94010
- Research Site 3302-0
-
-
-
-
Brussels Capital
-
Brussels、Brussels Capital、ベルギー、1200
- Research Site 3201-0
-
-
Gent
-
Ghent、Gent、ベルギー、9000
- Research Site 3204-0
-
-
Jette
-
Jette、Jette、ベルギー、1090
- Research Site 3205-0
-
-
Leuven
-
Leuven、Leuven、ベルギー、3000
- Research Site 3203-0
-
-
Liege
-
Liège、Liege、ベルギー、4000
- Research Site 3207-0
-
-
Roeselare
-
Roeselare、Roeselare、ベルギー、8800
- Research Site 3202-0
-
-
-
-
-
Krakow、ポーランド、31-501
- Research Site 4804-0
-
Poznan、ポーランド、61-866
- Research Site 4801-0
-
Warsaw、ポーランド、04-141
- Research Site 4805-0
-
Wroclaw、ポーランド、53-673
- Research Site 4809-0
-
-
Rzeszów
-
Rzeszów、Rzeszów、ポーランド、35-021
- Research Site 4802-0
-
-
Torun
-
Torun、Torun、ポーランド、87-100
- Research Site 4807-0
-
-
Łódź Voivodeship
-
Lodz、Łódź Voivodeship、ポーランド、90-302
- Research Site 4803-0
-
-
-
-
Anhui
-
Bengbu、Anhui、中国、233004
- Research Site 8639-0
-
Hefei、Anhui、中国、230088
- Research Site 8640-0
-
Hefei、Anhui、中国、230601
- Research Site 8614-0
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100021
- Research Site 8601-0
-
Beijing、Beijing Municipality、中国、100071
- Research Site 8625-0
-
Beijing、Beijing Municipality、中国、100142
- Research Site 8653-0
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400030
- Research Site 8627-0
-
-
Fujian
-
Fuzhou、Fujian、中国、350015
- Research Site 8651-0
-
Xiamen、Fujian、中国、361003
- Research Site 8638-0
-
-
Gansu
-
Lanzhou、Gansu、中国、730000
- Research Site 8630-0
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510000
- Research Site 8604-0
-
Guangzhou、Guangdong、中国、510060
- Research Site 8628-0
-
Huizhou、Guangdong、中国、516003
- Research Site 8621-0
-
Zhuhai、Guangdong、中国、519000
- Research Site 8622-0
-
-
Guangxi
-
Nanning、Guangxi、中国、530021
- Research Site 8615-0
-
-
Hebei
-
Baoding、Hebei、中国、071030
- Research Site 8629-0
-
Shijiazhuang、Hebei、中国、50011
- Research Site 8645-0
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150081
- Research Site 8619-0
-
-
Henan
-
Anyang、Henan、中国、455000
- Research Site 8649-0
-
Luoyang、Henan、中国、471003
- Research Site 8609-0
-
Weihui、Henan、中国、453100
- Research Site 8648-0
-
Zhengzhou、Henan、中国、450000
- Research Site 8605-0
-
Zhengzhou、Henan、中国、450003
- Research Site 8623-0
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Research Site 8637-0
-
Wuhan、Hubei、中国、430079
- Research Site 8608-0
-
Xiangyang、Hubei、中国、430079
- Research Site 8633-0
-
-
Hunan
-
Changsha、Hunan、中国、410005
- Research Site 8635-0
-
Yongzhou、Hunan、中国、425000
- Research Site 8654-0
-
-
Jiangsu
-
Huai'an、Jiangsu、中国、223300
- Research Site 8646-0
-
Nanjing、Jiangsu、中国、210029
- Research Site 8607-0
-
Xuzhou、Jiangsu、中国、221009
- Research Site 8624-0
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330009
- Research Site 8631-0
-
-
Jilin
-
Changchun、Jilin、中国、130000
- Research Site 8612-0
-
Changchun、Jilin、中国、130021
- Research Site 8618-0
-
Changchun、Jilin、中国、130041
- Research Site 8644-0
-
-
Liaoning
-
Dalian、Liaoning、中国、116027
- Research Site 8636-0
-
Shenyang、Liaoning、中国、110001
- Research Site 8643-0
-
Shenyang、Liaoning、中国、110042
- Research Site 8642-0
-
-
Shandong
-
Jinan、Shandong、中国、250117
- Research Site 8634-0
-
Jining、Shandong、中国、272029
- Research Site 8613-0
-
Linyi、Shandong、中国、276000
- Research Site 8610-0
-
Weihai、Shandong、中国、264200
- Research Site 8650-0
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200025
- Research Site 8603-0
-
Shanghai、Shanghai Municipality、中国、200032
- Research Site 8602-0
-
-
Shanxi
-
Xi’an、Shanxi、中国、710061
- Research Site 8611-0
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- Research Site 8606-0
-
Neijiang、Sichuan、中国、641000
- Research Site 8626-0
-
Zigong、Sichuan、中国、643000
- Research Site 8647-0
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300453
- Research Site 8617-0
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国、830000
- Research Site 8616-0
-
-
Yunnan
-
Kunming、Yunnan、中国、650118
- Research Site 8632-0
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310000
- Research Site 8652-0
-
Hangzhou、Zhejiang、中国、310016
- Research Site 8620-0
-
Hangzhou、Zhejiang、中国、310022
- Research Site 8641-0
-
-
-
-
-
Cheonan、韓国、31151
- Research Site 8212-0
-
Seoul、韓国、03080
- Research Site 8207-0
-
Seoul、韓国、06273
- Research Site 8213-0
-
Ulsan、韓国、44033
- Research Site 8214-0
-
-
Busan
-
Busan、Busan、韓国、49201
- Research Site 8208-0
-
-
Gangwon-do
-
Wŏnju、Gangwon-do、韓国、26426
- Research Site 8211-0
-
-
Gyeonggi-do
-
Seongnam-si、Gyeonggi-do、韓国、KS009
- Research Site 8204-0
-
Seoul、Gyeonggi-do、韓国、2841
- Research Site 8201-0
-
Suwon、Gyeonggi-do、韓国、16499
- Research Site 8202-0
-
-
Incheon
-
Incheon、Incheon、韓国、21565
- Research Site 8209-0
-
-
Seoul
-
Seoul、Seoul、韓国、3722
- Research Site 8206-0
-
Seoul、Seoul、韓国、5505
- Research Site 8210-0
-
Seoul、Seoul、韓国、6591
- Research Site 8203-0
-
Seoul、Seoul、韓国、8308
- Research Site 8205-0
-
-
-
-
-
Hong Kong、香港、00000
- Research Site 8504-0
-
Hong Kong、香港、0000
- Research Site 8501-0
-
Hong Kong、香港、0000
- Research Site 8503-0
-
-
Hong Kong
-
Hong Kong、Hong Kong、香港
- Research Site 8502-0
-
Hong Kong、Hong Kong、香港
- Research Site 8505-0
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
1. Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).
2. Pathologically documented breast cancer that:
- Is advanced or metastatic
- Has HER2-low expression (IHC 1+ or IHC 2+/ISH-) as determined by the central laboratory result.
- Was never previously reported as HER2-positive (IHC 3+ or ISH+) as per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines.
- Is documented as HR+ (either estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR ≥1%]) per ASCO/CAP guidelines (Allison et al 2020).
3. Must have an adequate tumor tissue sample available for assessment of HER2 by central laboratory, in formalin fixation and paraffin embedding (FFPE) blocks based on a mandatory FFPE tumor sample preferably obtained at the time of metastatic disease or later;
4. Eastern Cooperative Oncology Group performance status of 0 or 1.
5. Must have had either:
- Disease progression on endocrine therapy + CDK4/6 inhibitor within 6 months of starting first line treatment for metastatic disease and considered appropriate for chemotherapy as the next treatment by the investigator, OR
- Disease progression on at least 2 previous lines of ET with or without a targeted therapy (such as CDK4/6, mammalian target of rapamycin [mTOR] or phosphoinositide 3-kinase [PI3-K] inhibitors) administered for the treatment of metastatic disease.
6. No prior chemotherapy for advanced or metastatic breast cancer. Subjects who have received chemotherapy in the neo-adjuvant or adjuvant setting are eligible, as long as they have had a disease-free interval (defined as completion of systemic chemotherapy to diagnosis of advanced or metastatic disease) of >12 months.
7. Life expectancy ≥12 weeks at screening.
8. Subjects must have at least one measurable lesion as defined per RECIST v1.1 (For bone only disease, subjects with lytic or mixed lytic bone lesions that can be measured by CT or MRI are eligible; subjects with sclerotic/osteoblastic bone lesions are not eligible).
9. Has LVEF ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before randomization.
10. Adequate organ and bone marrow function within 14 days before randomization.
11. Has adequate treatment washout period before randomization.
12. Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of study treatment.
Women of childbearing potential are defined as those who are not surgically sterile (i.e., underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.
13. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions for 7 months after the last dose of study treatment. Not all methods of contraception are highly effective. Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the subject for the duration of the study treatment and the drug washout period (7 months). Periodic abstinence (e.g., calendar ovulation, symptothermal, post ovulation methods), the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female subjects must not donate ova, or retrieve for their own use, from the time of screening and throughout the study treatment period, and for at least 7 months after the last dose of study treatment. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to randomization in this study.
14. Non-sterilized male subjects who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening and throughout the duration of the study treatment and the washout period (4 months after the last dose of DB-1303, 6 months after the last dose of paclitaxel or nab-paclitaxel, and 3 months after the last dose of capecitabine). Abstinence is acceptable only as true abstinence when this is in line with the preferred and usual lifestyle of the subject for the duration of the study treatment and the drug washout period. Periodic abstinence (e.g., calendar ovulation, symptothermal, post ovulation methods), the rhythm method, and the withdrawal method are not acceptable methods of contraception. It is strongly recommended for the female partners of a male subject also use at least one highly effective method of contraception throughout this period. In addition, male subjects should refrain from fathering a child or donating sperm throughout the duration of the study and the washout period (4 months after the last dose of DB-1303, 6 months after the last dose of paclitaxel or nab paclitaxel, and 3 months after the last dose of capecitabine). Preservation of sperm should be considered prior to randomization in this study.
15. Must be able and willing to comply with the protocol requirements and must sign and date the informed consent form prior to any screening evaluations.
Exclusion Criteria:
- Ineligible for all options in the investigator's choice chemotherapy arm.
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events or compromise the ability of the subject to give written informed consent.
- Clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring repeated drainage, peritoneal shunt or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to the randomization.
- Uncontrolled or significant cardiovascular disease
- Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and radiation pneumonitis which needs glucocorticoids and antibiotics) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
- Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤ 1 or baseline or Grade ≤ 2 anemia.
- Previous treatment with anti-HER2 therapy.
- Prior treatment with antibody-drug conjugate that comprised an exatecan derivative that is a topoisomerase I inhibitor.
- Prior randomization or treatment in a previous DB-1303/BNT323 study regardless of treatment assignment.
- Has substance abuse or any other medical conditions such as psychological conditions, that may, in the opinion of the Investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results.
- Individuals who are dependent on the Sponsor, clinical site, or Investigator (e.g., is an employee of the Sponsor or the clinical trial site, a dependent of the Investigator, or any site staff member otherwise supervised by the Investigator).
- Individuals who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities, in accordance with local regulations.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:DB-1303/BNT323
Enrolled Subjects will be randomized to receive a 8 mg/kg IV dose of DB-1303/BNT323 on Day 1 of each cycle Q3W |
IV |
|
アクティブコンパレータ:investigator's choice single agent chemotherapy
Enrolled Subjects will be randomized to receive investigator's choice single agent chemotherapy (capecitabine:1000 or 1250 mg/m2, Oral, Twice daily orally for 2 weeks followed by a 1-week rest period in 3-week cycles; paclitaxel:80 mg/m2, IV, Every week (QW) in 3-week cycles; or nab-paclitaxel: 100 mg/m2, IV, Every week (QW) for 3 weeks followed by a one-week rest period in 4-week cycles) until RECIST 1.1 defined disease progression (PD), unless there is unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. |
Oral IV IV |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS) in the HR+, HER2-low population
時間枠:Up to approximately 51 months
|
PFS by BICR according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall survival (OS) in the HR+, HER2-low population
時間枠:Up to approximately 51 months
|
OS in the HR+, HER2-low population |
Up to approximately 51 months
|
|
Objective response rate (ORR) in the HR+, HER2-low population
時間枠:Up to approximately 51 months
|
ORR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
|
PFS by Investigator assessment
時間枠:Up to approximately 51 months
|
PFS by Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
|
Duration of response (DoR) in the HR+, HER2-low population
時間枠:Up to approximately 51 months
|
DoR by BICR and Investigator assessment according to RECIST 1.1 in the HR+, HER2-low population |
Up to approximately 51 months
|
|
Treatment-emergent adverse events (TEAEs)
時間枠:from the time of the subject signing the informed consent form (ICF) until the follow-up period is completed (35 days after the last dose of study treatment
|
TEAEs per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
from the time of the subject signing the informed consent form (ICF) until the follow-up period is completed (35 days after the last dose of study treatment
|
|
Serious adverse events (SAEs)
時間枠:from the time of the subject signing the ICF until the follow-up period is completed (35 days after the last dose of study treatment
|
SAEs per NCI CTCAE v5.0 |
from the time of the subject signing the ICF until the follow-up period is completed (35 days after the last dose of study treatment
|
|
Patient reported outcomes (PROs): European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) - C30
時間枠:Up to approximately 51 months
|
Change from baseline in the functioning/symptom/global quality of life (QoL) subscales of EORTC QLQ-C30. Scale scores range from 0-100. For functioning and global QoL scales, higher scores indicate better functioning or global health status. For symptom scales, higher scores indicate greater symptom burden. |
Up to approximately 51 months
|
|
Patient reported outcomes (PROs): EORTC QLQ-BR45
時間枠:Up to approximately 51 months
|
Change from baseline in the functioning/symptom subscales of EORTC QLQ-BR45. Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden. |
Up to approximately 51 months
|
|
Patient reported outcomes (PROs): European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)
時間枠:Up to approximately 51 months
|
Change from baseline in EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. VAS score range from 0-100, higher scores indicate better health status. |
Up to approximately 51 months
|
|
European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L)
時間枠:Up to approximately 51 months
|
EQ-5D-5L health state utility index score and Visual Analogue Scale (VAS) score. The change from baseline value will be reported. |
Up to approximately 51 months
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Joyce O'Shaughnessy, PHD、Texas Oncology - Baylor Charles A. Sammons Cancer center
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- DB-1303-O-3002
- CTR20233708 (その他の識別子:CENTER FOR DRUG EVALUATION, NMPA)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。